Top

Published in:

Open Access 01-12-2023 | Dyslipidemia | Research

Primary hyperparathyroidism in young patients is associated with metabolic disorders: a prospective comparative study

Authors: Ekaterina E. Bibik, Ekaterina A. Dobreva, Alina R. Elfimova, Anastasiia P. Miliutina, Anna K. Eremkina, Anna M. Gorbacheva, Julia A. Krupinova, Ekaterina O. Koksharova, Igor A. Sklyanik, Alexander Y. Mayorov, Natalia G. Mokrysheva

Published in: BMC Endocrine Disorders | Issue 1/2023

Abstract

Background

Components of metabolic syndrome can be observed in patients with primary hyperparathyroidism (PHPT). The link between these disorders remains unclear due to the lack of relevant experimental models and the heterogeneity of examined groups. The effect of surgery on metabolic abnormalities is also controversial. We conducted a comprehensive assessment of metabolic parameters in young patients with PHPT.

Methods

One-center prospective comparative study was carried out. The participants underwent a complex biochemical and hormonal examination, a hyperinsulinemic euglycemic and hyperglycemic clamps, a bioelectrical impedance analysis of the body composition before and 13 months after parathyroidectomy compared to sex-, age- and body mass index matched healthy volunteers.

Results

45.8% of patients (n = 24) had excessive visceral fat. Insulin resistance was detected in 54.2% of cases. PHPT patients had higher serum triglycerides, lower M-value and higher C-peptide and insulin levels in both phases of insulin secretion compared to the control group (p < 0.05 for all parameters). There were tendencies to decreased fasting glucose (p = 0.031), uric acid (p = 0.044) and insulin levels of the second secretion phase (p = 0.039) after surgery, but no statistically significant changes of lipid profile and M-value as well as body composition were revealed. We obtained negative correlations between percent body fat and osteocalcin and magnesium levels in patients before surgery.

Conclusion

PHPT is associated with insulin resistance that is the main risk factor of serious metabolic disorders. Surgery may potentially improve carbohydrate and purine metabolism.

Kytikova OY, Antonyuk MV, Kantur TA, Novgorodtseva TP, Denisenko YK. Prevalence and biomarkers in metabolic syndrome. Obes Metab. 2021;18(3):302–12. https://doi.org/10.14341/omet12704. In Russ.CrossRef

Corbetta S, Mantovani G, Spada A. Metabolic Syndrome in Parathyroid Diseases. Front Horm Res. 2018;49:67–84. https://doi.org/10.1159/000486003.CrossRefPubMed

Procopio M, Barale M, Bertaina S, et al. Cardiovascular risk and metabolic syndrome in primary hyperparathyroidism and their correlation to different clinical forms. Endocrine. 2014;47(2):581–9. https://doi.org/10.1007/s12020-013-0091-z.CrossRefPubMed

Pepe J, Cipriani C, Sonato C, et al. Cardiovascular manifestations of primary hyperparathyroidism: a narrative review. Eur J Endocrinol. 2017;177(6):R297–308. https://doi.org/10.1530/eje-17-0485.CrossRefPubMed

Tassone F, Procopio M, Gianotti L, et al. Insulin resistance is not coupled with defective insulin secretion in primary hyperparathyroidism. Diabet Med. 2009;26(10):968–73. https://doi.org/10.1111/j.1464-5491.2009.02804.x.CrossRefPubMed

Beysel S, Caliskan M, Kizilgul M, et al. Parathyroidectomy improves cardiovascular risk factors in normocalcemic and hypercalcemic primary hyperparathyroidism. BMC Cardiovasc Disord. 2019;19(1):106. https://doi.org/10.1186/s12872-019-1093-4.CrossRefPubMedPubMedCentral

Bibik EE, Eremkina AK, Krupinova JA, et al. Impaired glucose metabolism and other metabolic disorders in patients with primary hyperparathyroidism. Diabetes mellitus. 2020;23(5):459–66. https://doi.org/10.14341/DM12436. In Russ.CrossRef

Khan AA, Hanley DA, Rizzoli R, et al. Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos Int. 2017;28(1):1–19. https://doi.org/10.1007/s00198-016-3716-2.CrossRefPubMed

Mokrysheva NG, Eremkina AK, Krupinova YA, et al. The clinical practice guidelines for primary hyperparathyroidism, short version. Problems of Endocrinology. 2021;67(4):94–124. https://doi.org/10.14341/probl12801. In Russ.CrossRefPubMed

10.

Chang E, Donkin SS, Teegarden D. Parathyroid hormone suppresses insulin signaling in adipocytes. Mol Cell Endocrinol. 2009;307(1–2):77–82. https://doi.org/10.1016/j.mce.2009.03.024.CrossRefPubMedPubMedCentral

11.

Reusch JE, Begum N, Sussman KE, Draznin B. Regulation of GLUT-4 phosphorylation by intracellular calcium in adipocytes. Endocrinology. 1991;129(6):3269–73. https://doi.org/10.1210/endo-129-6-3269.CrossRefPubMed

12.

Cvijovic G, Micic D, Kendereski A, et al. The effect of parathyroidectomy on insulin sensitivity in patients with primary hyperparathyroidism - an never ending story? Exp Clin Endocrinol Diabetes. 2015;123(6):336–41. https://doi.org/10.1055/s-0035-1549906.CrossRefPubMed

13.

Prager R, Schernthaner G, Niederle B, Roka R. Evaluation of glucose tolerance, insulin secretion, and insulin action in patients with primary hyperparathyroidism before and after surgery. Calcif Tissue Int. 1990;46(1):1–4. https://doi.org/10.1007/BF02555816.CrossRefPubMed

14.

Querfeld U, Hoffmann MM, Klaus G, et al. Antagonistic effects of vitamin D and parathyroid hormone on lipoprotein lipase in cultured adipocytes. J Am Soc Nephrol. 1999;10(10):2158–64. https://doi.org/10.1681/asn.v10102158.CrossRefPubMed

15.

Bao Y, Ma X, Yang R, et al. Inverse relationship between serum osteocalcin levels and visceral fat area in Chinese men. J Clin Endocrinol Metab. 2013;98(1):345–51. https://doi.org/10.1210/jc.2012-2906.CrossRefPubMed

16.

Gianotti L, Piovesan A, Croce CG, et al. Interplay between serum osteocalcin and insulin sensitivity in primary hyperparathyroidism. Calcif Tissue Int. 2011;88(3):231–7. https://doi.org/10.1007/s00223-010-9453-1.CrossRefPubMed

17.

Mendonca ML, Batista SL, Nogueira-Barbosa MH, et al. Primary Hyperparathyroidism: The Influence of Bone Marrow Adipose Tissue on Bone Loss and of Osteocalcin on Insulin Resistance. Clinics (Sao Paulo). 2016;71(8):464–9. https://doi.org/10.6061/clinics/2016(08)09.CrossRefPubMed

18.

Delfini E, Petramala L, Caliumi C, et al. Circulating leptin and adiponectin levels in patients with primary hyperparathyroidism. Metabolism. 2007;56(1):30–6. https://doi.org/10.1016/j.metabol.2006.08.019.CrossRefPubMed

19.

Lopez I, Pineda C, Raya AI, et al. Leptin directly stimulates parathyroid hormone secretion. Endocrine. 2017;56:675–8. https://doi.org/10.1007/s12020-016-1207-z.CrossRefPubMed

20.

Hoang D, Broer N, Sosa JA, et al. Leptin Is Produced by Parathyroid Glands and Stimulates Parathyroid Hormone Secretion. Ann Surg. 2017;266(6):1075–83. https://doi.org/10.1097/sla.0000000000002004.CrossRefPubMed

21.

Ponvilawan B, Charoenngam N, Ungprasert P. Primary hyperparathyroidism is associated with a higher level of serum uric acid: A systematic review and meta-analysis. Int J Rheum Dis. 2020;23(2):174–80. https://doi.org/10.1111/1756-185x.13740.CrossRefPubMed

22.

Ljunghall S, Palmer M, Akerstrom G, Wide L. Diabetes mellitus, glucose tolerance and insulin response to glucose in patients with primary hyperparathyroidism before and after parathyroidectomy. Eur J Clin Invest. 1983;13(5):373–7. https://doi.org/10.1111/j.1365-2362.1983.tb00116.x.CrossRefPubMed

23.

Nikooei Noghani S, Milani N, et al. Assessment of insulin resistance in patients with primary hyperparathyroidism before and after Parathyroidectomy. Endocrinol Diabetes Metab. 2021;4(4):e00294. https://doi.org/10.1002/edm2.294.CrossRefPubMedPubMedCentral

24.

Hagstrom E, Lundgren E, Lithell H, et al. Normalized dyslipidaemia after parathyroidectomy in mild primary hyperparathyroidism: population-based study over five years. Clin Endocrinol (Oxf). 2002;56(2):253–60. https://doi.org/10.1046/j.0300-0664.2001.01468.x.CrossRefPubMed

25.

Almqvist EG, Bondeson A-G, Bondeson L, et al. Factors influencing insulin sensitivity in patients with mild primary hyperparathyroidism before and after parathyroidectomy. Scand J Clin Lab Invest. 2012;72(2):92–9. https://doi.org/10.3109/00365513.2011.634432.CrossRefPubMed

26.

Godang K, Lundstam K, Mollerup C, et al. The effect of surgery on fat mass, lipid and glucose metabolism in mild primary hyperparathyroidism. Endocr Connect. 2018;7(8):941–8. https://doi.org/10.1530/EC-18-0259.CrossRefPubMedPubMedCentral

27.

Ishay A, Herer P, Luboshitzky R. Effects of successful parathyroidectomy on metabolic cardiovascular risk factors in patients with severe primary hyperparathyroidism. Endocr Pract. 2011;17(4):584–90. https://doi.org/10.4158/ep10321.or.CrossRefPubMed

28.

Yavari M, Feizi A, Haghighatdoost F, et al. The influence of parathyroidectomy on cardiometabolic risk factors in patients with primary hyperparathyroidism: a systematic review and meta-analysis. Endocrine. 2021;72(1):72–85. https://doi.org/10.1007/s12020-020-02519-7.CrossRefPubMed

29.

van Wijk JPH, Dreijerink KMA, Pieterman CRC, et al. Increased prevalence of impaired fasting glucose in MEN1 gene mutation carriers. Clin Endocrinol (Oxf). 2012;76(1):67–71. https://doi.org/10.1111/j.1365-2265.2011.04166.x.CrossRefPubMed

30.

Chen J, Wu C, Wang X, et al. The Impact of COVID-19 on Blood Glucose: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne). Front Endocrinol. 2020;11:574541. https://doi.org/10.3389/fendo.2020.574541.CrossRef

31.

Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr. 2020;14(4):303–10. https://doi.org/10.1016/j.dsx.2020.04.004.CrossRefPubMedPubMedCentral

32.

Cuschieri S, Grech S. COVID-19 and diabetes: The why, the what and the how. J Diabetes Complications. 2020;34(9):107637. https://doi.org/10.1016/j.jdiacomp.2020.107637.CrossRefPubMedPubMedCentral

Title: Primary hyperparathyroidism in young patients is associated with metabolic disorders: a prospective comparative study
Authors: Ekaterina E. Bibik
Ekaterina A. Dobreva
Alina R. Elfimova
Anastasiia P. Miliutina
Anna K. Eremkina
Anna M. Gorbacheva
Julia A. Krupinova
Ekaterina O. Koksharova
Igor A. Sklyanik
Alexander Y. Mayorov
Natalia G. Mokrysheva
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Dyslipidemia
Hyperparathyroidism
Insulins
Parathyroidectomy
Parathyroidectomy
Insulins
Published in: BMC Endocrine Disorders / Issue 1/2023
Electronic ISSN: 1472-6823
DOI: https://doi.org/10.1186/s12902-023-01302-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

Effects of selenium supplementation on Polycystic Ovarian Syndrome: a systematic review and meta-analysis on randomized clinical trials

Mediastinal parathyroid carcinoma: a case report and review of the literature

Dietary selenium intake in relation to non-alcoholic fatty liver disease assessed by fatty liver index and hepatic steatosis index; a cross-sectional study on the baseline data of prospective PERSIAN Kavar cohort study.

Pharmacodynamic and pharmacokinetic properties of the combined preparation of levothyroxine plus sustained- release liothyronine; a randomized controlled clinical trial

Central precocious puberty secondary to peripheral precocious puberty due to a pineal germ cell tumor: a case and review of literature

Correction: Inadequate care and excessive overprotection during childhood are associated with the presence of Diabetes Mellitus in adulthood in a general Japanese population: a cross-sectional analysis from the Hisayama Study

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials